Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283788 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization
A Phase 1 study of Epilepsy, sponsored by Bial - Portela C S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 1
- Study location
NCT02283788 is a Phase 1 study of Epilepsy that has completed, run by Bial - Portela C S.A.. The registered enrollment target is 67 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02283788, a Phase 1 study of Epilepsy, has completed, sponsored by Bial - Portela C S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG BIA 2-093
Study Locations (1)
Florida
- Comprehensive Phase OneTM - Miramar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02283788
The ClinicalTrials.gov registry entry for NCT02283788 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (93% lower). The listed sponsor is Bial - Portela C S.A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02283788 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02283788 about?
NCT02283788 is a clinical study titled "Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization". A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women
What is the current status of trial NCT02283788?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2007-03. Estimated completion is 2007-06.
What conditions does trial NCT02283788 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT02283788?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), BIA 2-093 (DRUG).
Who is sponsoring clinical trial NCT02283788?
This trial is sponsored by Bial - Portela C S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02283788 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Ketamine's Dissociative Effects (KD Study)
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.